Individualized HCC surveillance using risk stratification scores in advanced fibrosis and cirrhotic HCV patients who achieved SVR : Prospective study
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.18291 ↗At a glance
Journal article in Alimentary Pharmacology & Therapeutics, 2025. Written by Gamal Shiha and 11 co-authors. Institution: Hepatology and Gastroenterology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt. Major MEDLINE topics: Liver Neoplasms, Carcinoma, Hepatocellular, Liver Cirrhosis, Hepatitis C, Chronic. Cited 13 times so far (Crossref); 36 references.
Abstract (original language)
Background
Several HCC risk stratification scores were developed; however, none has been prospectively validated. The primary aim is to validate the clinical utility of six HCC risk scores in large prospective study of F3‐4 patients achieving SVR following DAAs according to EASL guidelines. The secondary aim is to explore whether individualized risk stratification improves detection of HCC at early stages amenable to curative treatment.
Methods
This prospective study included two cohorts: Egyptian Liver Research Institute and Hospital (ELRIAH) cohort of 463 chronic HCV patients with advanced liver disease (F3 and F4) achieved SVR with a follow‐up every 6 months according to EASL guidelines using 6 simple HCC risk scores and Tanta cohort of 492 comparable patients where individualized surveillance intervals were tailored based on HCC risk assessments using GES score as follows: low‐risk patients were followed yearly, intermediate‐risk every 6 months and high‐risk every 2–3 months.
Results
All scores, except Watanabe post, successfully stratified patients into low‐, intermediate‐ and high‐risk groups, with log‐rank p ‐value of 0.001 and Harrell's C ranging from 0.669 to 0.728. Clinical utility of these scores revealed that the highest percentage of patients classified as low risk was 42.5% using the GES, while the lowest was 8.9% using the aMAP. ELRIAH cohort, 25 patients developed HCC with 52% diagnosed at BCLC 0 and A. Tanta cohort, 35 patients developed HCC, with 80% diagnosed at BCLC 0 and A.
Conclusion
Individualized risk stratification using HCC risk scores was associated with improved early‐stage detection and receipt of curative treatment.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Hepatology and Gastroenterology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
- Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt.
- Higher Institute of Applied Medical Sciences, Mansoura, Egypt.
- Tropical Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
- Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt.
- Biostatistics and Cancer Epidemiology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
ORCID profiles: Gamal Shiha, Riham Soliman
Cite
APA
Shiha, G., Hassan, A., Mousa, N., El-Domiaty, N., Mikhail, N., Gameaa, R., Kobtan, A., El Bassat, H., Sharaf-Eldin, M., Waked, I., Eslam, M., & Soliman, R. (2025). Individualized HCC surveillance using risk stratification scores in advanced fibrosis and cirrhotic HCV patients who achieved SVR : Prospective study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18291
Vancouver
Shiha G, Hassan A, Mousa N, El-Domiaty N, Mikhail N, Gameaa R, et al. Individualized HCC surveillance using risk stratification scores in advanced fibrosis and cirrhotic HCV patients who achieved SVR : Prospective study. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.18291
BibTeX
@article{Shiha2025,
author = {Shiha, Gamal and Hassan, Ayman and Mousa, Nasser and El-Domiaty, Nada and Mikhail, Nabiel and Gameaa, Reham and Kobtan, Abdelrahman and El Bassat, Hanan and Sharaf-Eldin, Mohamed and Waked, Imam and Eslam, Mohamed and Soliman, Riham},
title = {Individualized HCC surveillance using risk stratification scores in advanced fibrosis and cirrhotic HCV patients who achieved SVR : Prospective study},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.18291}
}
EUVIMED